Zanamivir Treatment Is Equally Effective for Both Influenza A and Influenza B
To the Editor-We previously reported that oseltamivir was less effective against influenza B than it was against influenza A in a study of the 2002-2003 influenza season; these findings were similar to those in a report in 2007 by Sugaya et al. [1] [2] [3] . However, the effectiveness of another neuraminidase inhibitor, zanamivir, has not been compared between influenza A and influenza B. Therefore, we performed a preliminary study of the effectiveness of zanamivir for the treatment of 67 patients with influenza A and 100 patients with influenza B (with influenza being diagnosed using commercial antigen detection kits) [3, 4] [3] . In addition, the mean duration of fever (‫ע‬SD) after onset of fever was 82.4 ‫ע‬ h and h in patients with 36.0 78.3 ‫ע‬ 41.9 influenza A and patients with influenza B, respectively, who were not treated with antiinfluenza drugs [3] .
Studies of in vitro antiviral activity of oseltamivir or zanamivir against laboratory strains of influenza virus that used culture and enzymatic assays have suggested that influenza B virus is less susceptible than influenza A virus to oseltamivir and zanamivir [5] . However, the reported difference of the mean inhibitory concentration of 50% between influenza A and B viruses was less for zanamivir (2.09 nM vs. 4.15 nM) than it was for oseltamivir (0.73 nM vs. 11.53 nM). These findings may explain our results in a clinical context, showing that oseltamivir is less effective against influenza B than it is against influenza A and that zanamivir is equally effective against both. We are now studying the effectiveness of zanamivir against influenza A and influenza B among a large number of patients identified during the 2006-2007 season. In conclusion, zanamivir is more effective than oseltamivir for the treatment of influenza B. previously published clinical trial that compared the efficacy of voriconazole therapy with that of amphotericin B therapy [2] . The "typical" CT images associated with invasive fungal disease are the halo sign and the air-crescent sign, which were present in 60.9% and 10.2% of patients, respectively [1] . The authors described 13 other image appearances that are considered to be less specific for invasive fungal disease. Interestingly, the presence of a halo sign at baseline was associated with a significantly higher global response rate and better survival. This difference in outcome was not explained by other factors, such as neutropenic status or underlying disease [1] .
Caillot et al. [3, 4] noted that the halo sign was the earliest radiological manifestation of invasive pulmonary aspergillosis in neutropenic patients and that nonspecific images and the air-crescent sign became more prevalent later in the course of the disease ( figure 1) . Thus, the improved outcome experienced among patients with a halo sign observed by Greene et al. [1] could have been a result of the earlier initiation of antifungal therapy in the course of the fungal disease. This would also explain why improved outcome was observed regardless of whether patients were treated with voriconazole or amphotericin B.
Timing is crucial for successful therapy of invasive Candida infections [5] , because the survival rate of patients treated immediately after blood cultures were obtained was better than that of patients in whom administration of antifungal therapy was delayed. There is no reason to assume that the management of other invasive fungal diseases would be any different. These observations underscore the importance of reducing the delay in the administration of effective treatment for patients with invasive fungal infection.
As indicated in figure 1 , the frequencies of the halo sign and the air-crescent sign encountered in the study by Greene et al. [1] can be superimposed on the figure based on the study by Caillot et al. [4] and likely correspond with a delay in diagnosis of ∼72 h. Caillot et al. [4] obtained prompt CT imaging of patients in whom invasive aspergillosis was suspected, whereas the current clinical practice is more in line with the study by Greene et al. [1] , in which a delay of several days before a CT was performed was not uncommon. Given the importance of early initiation of antifungal therapy, we should no longer accept a delay in obtaining the diagnostic information necessary for the optimum treatment of patients with suspected invasive fungal disease.
